Cargando…
How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework
OBJECTIVES: To review the pragmatism of published randomized trials of remdesivir and favipiravir based on the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) framework. STUDY DESIGN AND SETTING: Ten eligible trials were identified from an existing comprehensive living review and were e...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576695/ https://www.ncbi.nlm.nih.gov/pubmed/36265553 http://dx.doi.org/10.1016/j.jclinepi.2022.10.013 |
_version_ | 1784811590088916992 |
---|---|
author | Sharma, Tanmay Qamar, Intisar Zwarenstein, Merrick |
author_facet | Sharma, Tanmay Qamar, Intisar Zwarenstein, Merrick |
author_sort | Sharma, Tanmay |
collection | PubMed |
description | OBJECTIVES: To review the pragmatism of published randomized trials of remdesivir and favipiravir based on the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) framework. STUDY DESIGN AND SETTING: Ten eligible trials were identified from an existing comprehensive living review and were evaluated across the nine PRECIS-2 domains by two independent reviewers. RESULTS: All 10 trials had mostly pragmatic design characteristics. Four of the domains (i.e., recruitment, setting, organization, and primary analysis) were found to be pragmatic with most trials scoring four or five across the two interventions. In comparison scores for four other design domains (i.e., eligibility, follow-up, flexibility of delivery, and primary outcome) varied across the trials with some design choices being more explanatory. CONCLUSION: In our descriptive review of randomized controlled trails for two drugs for patients infected with COVID-19 early in the pandemic, we found that most trials had more pragmatic than explanatory characteristics. Some design choices for some of the trials, however, were not consistent with the urgent goal of informing clinical decision making in an epidemic. PRECIS-2 should be used as a guide by trialists, to help them match their trial design choices to the intended purpose of their trial. |
format | Online Article Text |
id | pubmed-9576695 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95766952022-10-18 How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework Sharma, Tanmay Qamar, Intisar Zwarenstein, Merrick J Clin Epidemiol Covid-19 Series OBJECTIVES: To review the pragmatism of published randomized trials of remdesivir and favipiravir based on the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS-2) framework. STUDY DESIGN AND SETTING: Ten eligible trials were identified from an existing comprehensive living review and were evaluated across the nine PRECIS-2 domains by two independent reviewers. RESULTS: All 10 trials had mostly pragmatic design characteristics. Four of the domains (i.e., recruitment, setting, organization, and primary analysis) were found to be pragmatic with most trials scoring four or five across the two interventions. In comparison scores for four other design domains (i.e., eligibility, follow-up, flexibility of delivery, and primary outcome) varied across the trials with some design choices being more explanatory. CONCLUSION: In our descriptive review of randomized controlled trails for two drugs for patients infected with COVID-19 early in the pandemic, we found that most trials had more pragmatic than explanatory characteristics. Some design choices for some of the trials, however, were not consistent with the urgent goal of informing clinical decision making in an epidemic. PRECIS-2 should be used as a guide by trialists, to help them match their trial design choices to the intended purpose of their trial. Elsevier Inc. 2022-12 2022-10-18 /pmc/articles/PMC9576695/ /pubmed/36265553 http://dx.doi.org/10.1016/j.jclinepi.2022.10.013 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Covid-19 Series Sharma, Tanmay Qamar, Intisar Zwarenstein, Merrick How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework |
title | How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework |
title_full | How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework |
title_fullStr | How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework |
title_full_unstemmed | How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework |
title_short | How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework |
title_sort | how pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of covid-19: a descriptive methodological review of trial design using the precis-2 framework |
topic | Covid-19 Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576695/ https://www.ncbi.nlm.nih.gov/pubmed/36265553 http://dx.doi.org/10.1016/j.jclinepi.2022.10.013 |
work_keys_str_mv | AT sharmatanmay howpragmaticarerandomizedtrialsofremdesivirandfavipiravirforinhospitaltreatmentofcovid19adescriptivemethodologicalreviewoftrialdesignusingtheprecis2framework AT qamarintisar howpragmaticarerandomizedtrialsofremdesivirandfavipiravirforinhospitaltreatmentofcovid19adescriptivemethodologicalreviewoftrialdesignusingtheprecis2framework AT zwarensteinmerrick howpragmaticarerandomizedtrialsofremdesivirandfavipiravirforinhospitaltreatmentofcovid19adescriptivemethodologicalreviewoftrialdesignusingtheprecis2framework |